Les nouveaux parcours en oncologie thoracique en 2017

Treatment for metastatic non-small-cell lung cancer is evolving from the use of cytotoxic chemotherapy to personalized treatment based on molecular alterations in some patients and to the harnessing of the immune system in the others. Therefore, due to its complexity and multidisciplinarity, cancer care is increasingly being delivered by multidisciplinary tumor boards. Furthermore, it is now possible to study complex genomic alterations in cancer using next-generation sequencing and this has led to the incorporation of these complex data into routine clinical practice. Within many major cancer centers, molecular tumor boards and clinics dedicated to the new approaches are organized. We review in the current article some of the important changes that took part in the improvement of the care of lung cancer patients.